John F Seymour
Overview
Explore the profile of John F Seymour including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
407
Citations
16325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kater A, Harrup R, Kipps T, Eichhorst B, Owen C, Assouline S, et al.
Blood
. 2025 Feb;
PMID: 40009494
Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial (NCT02005471) resulted in superior progression-free survival (PFS) and overall survival (OS) vs bendamustine-rituximab...
2.
Brown J, Seymour J, Jurczak W, Aw A, Wach M, Illes A, et al.
N Engl J Med
. 2025 Feb;
392(8):748-762.
PMID: 39976417
Background: Whether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown. Methods: In this phase...
3.
Erku D, Tobin J, Seymour J, MacManus M, Scuffham P, Hapgood G
EJHaem
. 2025 Feb;
6(1):e70002.
PMID: 39944796
Background: The TROG 99.03 trial demonstrated improved progression-free survival for patients with early-stage follicular lymphoma (FL) treated with systemic therapy using rituximab-cyclophosphamide, vincristine, prednisolone (R-CVP) after involved-field radiotherapy (RT) versus...
4.
Bennett R, Juneja M, Anderson M, Minson A, Herbert K, Lieschke G, et al.
Leuk Lymphoma
. 2025 Jan;
1-4.
PMID: 39810335
No abstract available.
5.
Simon F, Al-Sawaf O, Seymour J, Eichhorst B
Leukemia
. 2024 Dec;
39(1):25-28.
PMID: 39658627
Indolent mature B-cell neoplasms are a group of diseases in which recent therapeutic advances have led to an improved overall survival (OS) extending beyond several years. While cause of celebration...
6.
MacManus M, Seymour J, Tsang H, Fisher R, Keane C, Sabdia M, et al.
EBioMedicine
. 2024 Dec;
110:105468.
PMID: 39631145
Background: We report extended follow-up of TROG99.03, a randomised phase III trial in early-stage follicular lymphoma (ESFL) including new information on the role of adjuvant rituximab and translational studies. Methods:...
7.
Marzolini M, Qian W, Clifton-Hadley L, Patrick P, Warden J, Stevens L, et al.
Br J Haematol
. 2024 Nov;
206(3):876-886.
PMID: 39604791
Traditionally, patients with asymptomatic, advanced-stage follicular lymphoma were managed with a watchful-waiting approach until disease progression. The 'Watch and Wait' Phase-3 randomised international trial examined whether rituximab could delay the...
8.
Blombery P, de Jong D, Ferry J, Hsi E, Ondrejka S, Seymour J, et al.
Histopathology
. 2024 Oct;
86(1):69-78.
PMID: 39403047
The mature splenic B-cell lymphomas are an enigmatic group of lymphoid neoplasms that have long caused significant difficulty for the practicing pathologist due to overlapping diagnostic features among entities and...
9.
Yazdanpanah N, Sedikides C, Ochs H, Camargo Jr C, Darmstadt G, Cerda A, et al.
Adv Exp Med Biol
. 2024 Sep;
1457:1-31.
PMID: 39283418
Coronavirus disease 2019 (COVID-19) has affected not only individual lives but also the world and global systems, both natural and human-made. Besides millions of deaths and environmental challenges, the rapid...
10.
Hunter S, Ryland G, Pang J, Ninkovic S, Dun K, Seymour J, et al.
Leuk Lymphoma
. 2024 Sep;
65(14):2215-2218.
PMID: 39230950
No abstract available.